Oligonucleotide Therapeutic Patents

Antisense oligonucleotide (ASO) therapeutic patents cover ASO-mechanism innovations (RNase-H gapmer, splice-switching); chemical-modification innovations; oligonucleotide-chemistry innovations (morpholino, stereopure); and delivery and conjugate innovations — with IP held by the antisense pioneer, exon-skipping specialists, and next-generation chemistry/conjugate firms. MAJOR ASO PATENT HOLDERS: IONIS PHARMACEUTICALS (the antisense pioneer, deep estate): Spinraza (nusinersen, splice-switching for SMA, with Biogen — a blockbuster), Tegsedi/inotersen, Qalsody (tofersen, SOD1 ALS, with Biogen), Wainua (eplontersen), plus foundational 2′-MOE chemistry and gapmer design and a vast patent portfolio. SAREPTA THERAPEUTICS: phosphorodiamidate morpholino oligomer PMO exon-skipping drugs for Duchenne muscular dystrophy (Exondys 51/eteplirsen, Vyondys 53, Amondys 45) and peptide-conjugated PMO (PPMO). WAVE LIFE SCIENCES: stereopure oligonucleotide chemistry (PN backbone, controlling phosphorothioate chirality for improved potency/safety). AVIDITY BIOSCIENCES: antibody-oligonucleotide conjugates AOC (an antibody delivers the oligo to muscle). OTHERS: Biogen (partner/owner of several Ionis drugs), Stoke Therapeutics (TANGO splice-modulation upregulation), ProQR, Dyne (muscle-targeting), and academic foundational holders. ASO chemistry (2′-MOE, cEt, morpholino, stereopure) and tissue delivery are the core antisense patent domains.

RNase-H gapmer innovations; splice-switching and steric-block innovations; backbone and sugar chemical-modification innovations; and stereochemistry innovations represent core ASO patent domains — and antisense differs from siRNA in being a single strand acting by several distinct mechanisms. MECHANISM PATENTS: RNase-H1 'gapmer' ASOs (a central DNA gap flanked by modified wings recruits RNase H to cleave the target mRNA — the classic gene-silencing antisense mode), splice-switching/exon-skipping ASOs (steric-block oligos that bind pre-mRNA to redirect splicing WITHOUT degrading it — Spinraza upregulates SMN2, Sarepta skips dystrophin exons), translation-blocking, and microRNA inhibition (antagomirs); these mechanisms are claimed with specific sequences and chemistries. CHEMISTRY PATENTS: sugar modifications — 2′-O-methoxyethyl (2′-MOE, Ionis's workhorse), constrained ethyl (cEt), locked nucleic acid LNA, 2′-O-methyl/2′-fluoro; backbone — phosphorothioate (the standard, improving stability and protein binding) and phosphorodiamidate morpholino PMO (Sarepta's uncharged backbone, distinct chemistry); and stereopure phosphorothioate (Wave — defining the chirality at each linkage). ASO vs siRNA: ASOs are SINGLE-stranded and work by RNase H, splice-switching, or steric block; siRNAs are DOUBLE-stranded and work via the RISC/Argonaute pathway — different mechanisms, chemistries, and (importantly) different patent estates. The chemical-modification and stereochemistry, plus the specific sequence, are the most defensible ASO IP.

Morpholino-chemistry innovations; conjugate-delivery innovations; tissue-targeting innovations; and sequence composition-of-matter represent additional ASO patent domains — and delivery beyond the liver (especially to muscle and CNS) is the central antisense challenge. MORPHOLINO PATENTS: phosphorodiamidate morpholino oligomers PMO (a fundamentally different uncharged morpholine-ring backbone — Sarepta/Gene Tools heritage), and peptide-conjugated PMO (PPMO) that improve cell penetration and muscle delivery. CONJUGATE / DELIVERY PATENTS: GalNAc conjugation for hepatocyte delivery (shared concept with siRNA, enabling subcutaneous liver-targeted ASOs — Ionis LICA Ligand-Conjugated Antisense), antibody-oligonucleotide conjugates AOC for muscle (Avidity), receptor-targeting ligands, and intrathecal delivery for CNS (Spinraza/tofersen are dosed into the spinal fluid because oligos don't cross the blood-brain barrier). FORMULATION PATENTS: stability, lyophilization, and dosing-regimen patents. SEQUENCE PATENTS: the specific ASO sequence targeting a defined transcript region, as composition-of-matter (with its chemistry). Muscle-targeting conjugates (AOC, PPMO) and improved CNS delivery are the highest-value open ASO delivery IP, because the chemistry is mature but getting oligos into non-liver tissues remains the binding constraint.

ASO startup IP strategy must navigate Ionis's deep and broad antisense estate (2′-MOE, cEt, gapmer design, GalNAc-conjugated ASOs, many targets), Sarepta morpholino/exon-skipping patents, Wave stereopure-chemistry patents, Avidity conjugate patents, and a landscape where chemistry is mature and delivery is the frontier; understand that the durable asset is a specific ASO sequence + chemistry against a target plus a delivery solution, that broad chemistry (2′-MOE, phosphorothioate gapmer) is densely held by Ionis (FTO/licensing often needed), and that the open frontiers are tissue delivery (muscle, CNS, beyond liver) and novel chemistries/stereochemistry; identify whitespace in muscle/CNS-targeting conjugates, novel backbone/sugar chemistries, splice-modulation upregulation, and novel targets. ASO STARTUP IP STRATEGY: SEQUENCE + CHEMISTRY + DELIVERY ARE THE IP — CORE CHEMISTRY IS IONIS-HELD: patent the specific ASO sequence and its modification pattern against a target, but expect to license or design around Ionis's foundational 2′-MOE/cEt/gapmer/GalNAc estate; TISSUE DELIVERY (MUSCLE, CNS, BEYOND LIVER) IS HIGHEST-VALUE WHITESPACE: chemistry is mature; the binding constraint and biggest prize is getting oligos into non-liver tissues — antibody-oligonucleotide conjugates (Avidity), peptide-PMO, and CNS delivery are the open frontier; NOVEL CHEMISTRY/STEREOCHEMISTRY IS PATENTABLE: new backbones (beyond phosphorothioate), stereopure designs (Wave-style), and morpholino improvements are durable IP; SPLICE-MODULATION (INCLUDING UPREGULATION) IS A GROWING MECHANISM: steric-block ASOs that correct splicing or upregulate protein (Stoke TANGO) are a distinct, expanding patent area; DISTINGUISH FROM siRNA ESTATES: ASO and siRNA have different mechanisms and patent holders — map the right estate; WHEN TO PATENT: NOVEL ASO/DELIVERY WITH MEASURED ACTIVITY: file once a candidate shows measured results (target knockdown or splice-correction % + duration + tissue distribution + tolerability) — measured target modulation, duration, tissue delivery, and safety are the critical ASO IP metrics; KEY FTO CHECKLIST: Ionis 2'-MOE/cEt gapmer RNase-H, GalNAc LICA conjugate, splice-switching (Spinraza); Sarepta phosphorodiamidate morpholino PMO/PPMO exon-skipping; Wave stereopure PN phosphorothioate chirality; Avidity AOC antibody-oligonucleotide muscle; Stoke TANGO splice-upregulation; intrathecal CNS delivery; LNA; composition-of-matter ASO sequence; siRNA vs ASO mechanism/estate distinction.